Search Result

Results for "

VEGFR2 kinase

" in MedChemExpress (MCE) Product Catalog:

By Targets:	VEGFR (154) Acetyl-CoA Carboxylase (2) Akt (5) AMPK (2) Anaplastic lymphoma kinase (ALK) (3) Antibiotic (1) Apoptosis (48) Aurora Kinase (4) Autophagy (22) Bacterial (2) Bcl-2 Family (4) Bcr-Abl (5) Btk (1) c-Fms (7) c-Kit (21) c-Met/HGFR (14) Cadherin (2) Caspase (2) CDK (7) COX (1) Discoidin Domain Receptor (2) Drug Derivative (3) Drug Metabolite (2) EGFR (11) Endogenous Metabolite (1) Ephrin Receptor (2) ERK (4) FAK (2) FGFR (28) FLT3 (22) GSK-3 (3) HDAC (1) HIF/HIF Prolyl-Hydroxylase (1) HSV (2) IKK (1) Insulin Receptor (3) IRE1 (7) Isotope-Labeled Compounds (7) JAK (1) LRRK2 (1) MAP3K (1) MDM-2/p53 (1) MEK (3) Microtubule/Tubulin (1) Mitophagy (7) Mitosis (1) Mixed Lineage Kinase (2) MMP (3) mTOR (2) Necroptosis (1) NF-κB (2) NOD-like Receptor (NLR) (2) P-glycoprotein (1) p38 MAPK (3) PARP (2) PDGFR (57) Phosphodiesterase (PDE) (1) PI3K (2) Pim (1) Raf (7) Reactive Oxygen Species (ROS) (3) Reference Standards (24) RET (11) Src (17) STAT (2) Syk (1) TAM Receptor (8) Tie (8) Trk Receptor (6) Tyrosinase (1)
By Research Areas:	Cancer (146) Cardiovascular Disease (16) Endocrinology (2) Infection (8) Inflammation/Immunology (20) Metabolic Disease (4) Neurological Disease (3)

By Targets:

VEGFR (154)

Acetyl-CoA Carboxylase (2)

Akt (5)

AMPK (2)

Anaplastic lymphoma kinase (ALK) (3)

Antibiotic (1)

Apoptosis (48)

Aurora Kinase (4)

Autophagy (22)

Bacterial (2)

Bcl-2 Family (4)

Bcr-Abl (5)

Btk (1)

c-Fms (7)

c-Kit (21)

c-Met/HGFR (14)

Cadherin (2)

Caspase (2)

CDK (7)

COX (1)

Discoidin Domain Receptor (2)

Drug Derivative (3)

Drug Metabolite (2)

EGFR (11)

Endogenous Metabolite (1)

Ephrin Receptor (2)

ERK (4)

FAK (2)

FGFR (28)

FLT3 (22)

GSK-3 (3)

HDAC (1)

HIF/HIF Prolyl-Hydroxylase (1)

HSV (2)

IKK (1)

Insulin Receptor (3)

IRE1 (7)

Isotope-Labeled Compounds (7)

JAK (1)

LRRK2 (1)

MAP3K (1)

MDM-2/p53 (1)

MEK (3)

Microtubule/Tubulin (1)

Mitophagy (7)

Mitosis (1)

Mixed Lineage Kinase (2)

MMP (3)

mTOR (2)

Necroptosis (1)

NF-κB (2)

NOD-like Receptor (NLR) (2)

P-glycoprotein (1)

p38 MAPK (3)

PARP (2)

PDGFR (57)

Phosphodiesterase (PDE) (1)

PI3K (2)

Pim (1)

Raf (7)

Reactive Oxygen Species (ROS) (3)

Reference Standards (24)

RET (11)

Src (17)

STAT (2)

Syk (1)

TAM Receptor (8)

Tie (8)

Trk Receptor (6)

Tyrosinase (1)

By Research Areas:

Cancer (146)

Cardiovascular Disease (16)

Endocrinology (2)

Infection (8)

Inflammation/Immunology (20)

Metabolic Disease (4)

Neurological Disease (3)

169

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

GMP Molecules

Targets Recommended: VEGFR

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10255A

Sunitinib 90+ Cited Publications SU 11248	VEGFR PDGFR IRE1 Mitophagy Autophagy Apoptosis	Cancer
Sunitinib (SU 11248) is a multi-targeted receptor tyrosine kinase inhibitor with IC₅₀s of 80 nM and 2 nM for *VEGFR2* and PDGFRβ, respectively . Sunitinib, an ATP-competitive inhibitor, effectively inhibits autophosphorylation of Ire1α by inhibiting autophosphorylation and consequent RNase activation .

HY-12047

Ponatinib 45+ Cited Publications AP24534	Bcr-Abl PDGFR VEGFR FGFR Src Autophagy	Cancer
Ponatinib (AP24534) is an orally active multi-targeted kinase inhibitor with IC₅₀s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for Abl, PDGFRα, *VEGFR2, FGFR1, and Src*, respectively .

HY-10065

Axitinib 35+ Cited Publications AG-013736	VEGFR PDGFR	Cancer
Axitinib is a multi-targeted tyrosine kinase inhibitor with IC₅₀s of 0.1, 0.2, 0.1-0.3, 1.6 nM for *VEGFR1, VEGFR2, VEGFR3* and PDGFRβ, respectively.

HY-N0135

Tanshinone IIA Maximum Cited Publications 36 Publications Verification Dan Shen ketone	VEGFR	Cardiovascular Disease Cancer
Tanshinone IIA (Tan IIA) is one of the main compositions in the root of Salvia miltiorrhiza Bunge. Tanshinone IIA may suppress angiogenesis by targeting the protein kinase domains of *VEGF/VEGFR2*.

HY-10260

Vandetanib 25+ Cited Publications ZD6474	VEGFR Autophagy Apoptosis	Neurological Disease Inflammation/Immunology Cancer
Vandetanib (D6474) is a potent, orally active, and blood-brain-barrier penetrate inhibitor of *VEGFR2/KDR* tyrosine kinase activity (IC₅₀=40 nM). Vandetanib also has activity versus the tyrosine kinase activity of *VEGFR3/FLT4* (IC₅₀=110 nM) and *EGFR/HER1* (IC₅₀=500 nM) .

HY-10255

Sunitinib Malate 90+ Cited Publications SU 11248 Malate	PDGFR VEGFR IRE1 Mitophagy Autophagy Apoptosis	Infection Inflammation/Immunology Cancer
Sunitinib (SU 11248) Malat is a multi-targeted receptor tyrosine kinase inhibitor with IC₅₀s of 80 nM and 2 nM for *VEGFR2* and PDGFRβ, respectively . Sunitinib Malat, an ATP-competitive inhibitor, effectively inhibits autophosphorylation of Ire1α by inhibiting autophosphorylation and consequent RNase activation .

HY-10407

SU 5402 10+ Cited Publications	VEGFR FGFR PDGFR	Cancer
SU 5402 is a potent multi-targeted receptor tyrosine kinase inhibitor with IC₅₀ of 20 nM, 30 nM, and 510 nM for *VEGFR2, FGFR1, and PDGFRβ*, respectively.

HY-16961

Sitravatinib 5+ Cited Publications MGCD516; MG-516	VEGFR c-Kit FLT3 Discoidin Domain Receptor Trk Receptor	Inflammation/Immunology Cancer
Sitravatinib (MGCD516) is an orally bioavailable *receptor tyrosine kinase* (RTK) inhibitor with IC₅₀*s of 1.5 nM, 2 nM, 2 nM, 5 nM, 6 nM, 6 nM, 8 nM, 0.5 nM, 29 nM, 5 nM, and 9 nM for Axl, MER, VEGFR3, VEGFR2, VEGFR*1, KIT, FLT3, DDR2, DDR1, TRKA, TRKB, respectively . Sitravatinib shows potent single-agent antitumor efficacy and enhances the activity of PD-1 blockade through promoting an antitumor immune microenvironment .

HY-12044

Cabozantinib S-malate 55+ Cited Publications XL184 S-malate; BMS-907351 S-malate	VEGFR Apoptosis	Cancer
Cabozantinib S-malate (XL184 S-malate) is a potent multiple receptor tyrosine kinases inhibitor that inhibits *VEGFR2, c-Met, Kit, Axl* and Flt3 with IC₅₀s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.

HY-108766

Ponatinib hydrochloride 45+ Cited Publications AP24534 hydrochloride	Bcr-Abl FGFR PDGFR VEGFR Src Autophagy	Infection Cancer
Ponatinib hydrochloride (AP24534 hydrochloride) is a hydrochloride of ponatinib. Ponatinib is an orally active multi-targeted kinase inhibitor with IC₅₀s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for Abl, PDGFRα, *VEGFR2, FGFR1, and Src*, respectively .

HY-103002

SU5408 5 Publications Verification VEGFR2 kinase Inhibitor I	VEGFR	Cardiovascular Disease
SU5408 (VEGFR2 Kinase Inhibitor I) is a potent and cell-permeable inhibitor of *VEGFR2* kinase with an IC₅₀ of 70 nM.

HY-13302

CP-547632 1 Publications Verification	VEGFR FGFR	Cancer
CP-547632 is an orally active, ATP-competitive and potent *VEGFR-2* and FGF kinases inhibitor with IC₅₀s of 11 nM and 9 nM, respectively. CP-547632 is selective for VEGFR2 and bFGF over EGFR, PDGFRβ, and related tyrosine kinases (TKs). CP-547632 has antitumor efficacy .

HY-16025

EOC317 1 Publications Verification ACTB-1003	FGFR VEGFR	Cancer
EOC317 (ACTB-1003) is an oral kinase inhibitor with IC₅₀s of 6, 2 and 4 nM for FGFR1, *VEGFR2* and Tie-2.

HY-108713

Famitinib SHR1020	VEGFR PDGFR Apoptosis	Cancer
Famitinib (SHR1020), an orally active multi-targeted kinase inhibitor, inhibits the activity of c-kit, *VEGFR-2* and PDGFRβ with IC₅₀ values of 2.3 nM, 4.7 nM and 6.6 nM, respectively . Famitinib exerts powerful antitumor activity in human gastric cancer cells and xenografts. Famitinib triggers apoptosis .

HY-16265

JI-101	Ephrin Receptor PDGFR VEGFR	Cardiovascular Disease Cancer
JI-101 is an orally available multi-kinase inhibitor of *VEGFR2, PDGFRβ* and EphB4 with potent anti-cancer activity.

HY-13068

Golvatinib 4 Publications Verification E-7050	c-Met/HGFR VEGFR	Cancer
Golvatinib (E-7050) is a potent dual inhibitor of both c-Met and *VEGFR2* kinases with IC₅₀s of 14 and 16 nM, respectively.

HY-10372

PP121 4 Publications Verification	mTOR PDGFR VEGFR Src Apoptosis	Cancer
PP121 is a multi-targeted kinase inhibitor with IC₅₀s of 10, 60, 12, 14, 2 nM for mTOR, DNK-PK, *VEGFR2, Src, PDGFR*, respectively.

HY-107145A

Ningetinib 1 Publications Verification	TAM Receptor VEGFR c-Met/HGFR	Cancer
Ningetinib is a potent, orally bioavailable small molecule tyrosine kinase inhibitor (TKI) with IC₅₀s of 6.7, 1.9 and <1.0 nM for c-Met, *VEGFR2* and Axl, respectively.

HY-B0791

Altiratinib 1 Publications Verification DCC-2701	VEGFR c-Met/HGFR FLT3 Trk Receptor	Cancer
Altiratinib (DCC-2701) is a multi-targeted kinase inhibitor with IC₅₀s of 2.7, 8, 9.2, 9.3, 0.85, 4.6, 0.83 nM for MET, TIE2, *VEGFR2, FLT3, Trk1, Trk2, and Trk3* respectively.

HY-100419

BFH772	VEGFR	Cancer
BFH772 is a potent oral *VEGFR2* inhibitor, which is highly effective at targeting VEGFR2 kinase with an IC₅₀ value of 3 nM .

HY-15992

BIBF 1202 1 Publications Verification	VEGFR	Cancer
BIBF 1202 is the carboxylate metabolite of Nintedanib (HY-50904) which inhibits *VEGFR2* kinase with an IC₅₀ of 62 nM.

HY-10501

SU14813 1 Publications Verification	PDGFR VEGFR c-Kit	Cancer
SU14813 is a multi-targeted receptor tyrosine kinases inhibitor with IC₅₀s of 50, 2, 4, 15 nM for *VEGFR2, VEGFR1, PDGFRβ* and KIT.

HY-N8342

Rhamnazin 1 Publications Verification	VEGFR	Inflammation/Immunology Cancer
Rhamnazin is an orally active inhibitor of VEGFR2 signaling with an IC₅₀ of 4.68 μM against *VEGFR2* kinase. Rhamnazin shows potent antiangiogenic activity and antitumor efficacy . Rhamnazin shows antioxidant and anti-inflammatory properties .

HY-10991

MGCD-265 analog	c-Met/HGFR VEGFR Apoptosis	Cancer
MGCD-265 analog is a potent and oral active inhibitor of c-Met and *VEGFR2* tyrosine kinases, with IC₅₀s of 29 nM and 10 nM, respectively. MGCD-265 analog has significant antitumor activity .

HY-19986

AAL993	VEGFR	Cardiovascular Disease Cancer
IC₅₀s of 130 nM, 23 nM, and 18 nM for VEGFR1, VEGFR2, and VEGFR3, respectively. AAL993 shows less potently inhibits other tyrosine kinases. AAL993 possesses potent antiangiogenic and antitumor properties .

HY-111138

CZC-8004 CZC-00008004	EGFR VEGFR	Cancer
CZC-8004 (CZC-00008004) is a pan-kinase inhibitor. CZC-8004 has IC₅₀ values of 650 and 437 nM for EGFR WT and VEGFR2 V916M, respectively. CZC-8004 can be used in the study of cancer .

HY-147243

Ansornitinib ANG-3070	VEGFR PDGFR	Cardiovascular Disease Inflammation/Immunology
Ansornitinib is an orally active dual kinase inhibitor that inhibits platelet-derived growth factor receptor (PDGFR) and vascular endothelial growth factor receptor (VEGFR2). Ansornitinib can be used as an antifibrotic agent in lung, liver, kidney, and gastrointestinal fibrotic diseases .

HY-12047S

Ponatinib-d8 AP24534-d₈	Bcr-Abl PDGFR VEGFR FGFR Src Autophagy	Cancer
Ponatinib-d₈ (AP24534-d₈) is a deuterium labeled Ponatinib. Ponatinib (AP24534) is an orally active multi-targeted kinase inhibitor with IC50s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectively.

HY-U00437

Pz-1 1 Publications Verification	RET VEGFR Trk Receptor	Cardiovascular Disease Cancer
Pz-1 is a potent RET and *VEGFR2* inhibitor with IC₅₀s of less than 1 nM for both wild type kinases.

HY-13342AS

Apatinib-d8 free base YN968D1-d8 free base	Src VEGFR Autophagy c-Kit RET	Cancer
Apatinib-d₈ (free base) is the deuterium labeled Apatinib free base . Apatinib free base (YN968D1 free base) is an orally bioavailable tyrosine kinase inhibitor, which selectively targets VEGFR-2 (IC₅₀=1 nM). Apatinib free base (YN968D1 free base) is an anti-angiogenic drug for the research of advanced or metastatic gastric cancer. Apatinib free base (YN968D1 free base) potently inhibits Ret, c-Kit and c-Src with IC₅₀s of 13, 429 and 530 nM, respectively. It also inhibits cellular phosphorylation of VEGFR-2, c-kit and PDGFRβ .

HY-13302B

CP-547632 hydrochloride 1 Publications Verification	VEGFR FGFR	Cancer
CP-547632 hydrochloride is an orally active, ATP-competitive and potent *VEGFR-2* and FGF kinases inhibitor with IC₅₀s of 11 nM and 9 nM, respectively. CP-547632 hydrochloride is selective for VEGFR2 and bFGF over EGFR, PDGFRβ, and related tyrosine kinases (TKs). CP-547632 hydrochloride has antitumor efficacy .

HY-126319

SU5204	VEGFR EGFR	Cancer
SU5204, a tyrosine kinase inhibitor, has IC₅₀s of 4 and 51.5 μM for FLK-1 (VEGFR-2) and HER2, respectively .

HY-N7177

Hydroxytanshinone IIA	Drug Metabolite VEGFR	Cancer
Hydroxytanshinone IIA is a hydroxylated metabolite of Tanshinone IIA. Tanshinone IIA may suppress angiogenesis by targeting the protein kinase domains of *VEGF/VEGFR2* .

HY-10501A

SU14813 maleate	PDGFR VEGFR c-Kit	Cancer
SU14813 maleate is a multi-targeted receptor tyrosine kinases inhibitor with IC₅₀s of 50, 2, 4, 15 nM for *VEGFR2, VEGFR1, PDGFRβ* and KIT.

HY-18179

AZD2932	PDGFR VEGFR FLT3 c-Kit	Cancer
AZD2932 is a potent and multi-targeted kinase inhibitor *VEGFR2, PDGFβ, Flt-3* and c-Kit with IC₅₀s of 8, 4, 7 and 9 nM in cell assay, respectively.

HY-119757

Tyrphostin AG1433 SU1433; AG1433	PDGFR VEGFR	Cancer
Tyrphostin AG1433 (SU1433) is a tyrosine kinases inhibitor. AG1433 is also a selective PDGFRβ and VEGFR-2 (Flk-1/KDR) inhibitor with IC₅₀s of 5.0 μM and 9.3 μM, respectively. Tyrphostin AG1433 prevents blood vessel formation .

HY-13016S1

Cabozantinib-d4 XL184-d₄; BMS-907351-d₄	VEGFR c-Met/HGFR c-Kit TAM Receptor FLT3 Apoptosis	Cancer
Cabozantinib-d₄ is deuterium labeled Cabozantinib. Cabozantinib is a potent multiple receptor tyrosine kinases (RTKs) inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC50s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.

HY-108766R

Ponatinib hydrochloride (Standard) AP24534 hydrochloride (Standard)	Bcr-Abl FGFR PDGFR VEGFR Src Autophagy Reference Standards	Infection Cancer
Ponatinib (hydrochloride) (Standard) is the analytical standard of Ponatinib (hydrochloride). This product is intended for research and analytical applications. Ponatinib hydrochloride (AP24534 hydrochloride) is a hydrochloride of ponatinib. Ponatinib is an orally active multi-targeted kinase inhibitor with IC50s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectively .

HY-108713A

Famitinib malate SHR1020 malate	VEGFR PDGFR Apoptosis	Cancer
Famitinib (SHR1020) malate, an orally active multi-targeted kinase inhibitor, inhibits the activity of c-kit, *VEGFR-2* and PDGFRβ with IC₅₀ values of 2.3 nM, 4.7 nM and 6.6 nM, respectively. Famitinib malate induces cell apoptosis. Famitinib malate exerts powerful antitumor activity in human gastric cancer cells and xenografts, it can be used for the research of cancer .

HY-108933

JK-P3	VEGFR FGFR	Cancer
JK-P3 is a potent and pan *VEGFR2* inhibitor, with IC₅₀s of 7.83 μM, 27 μM and 5.18 μM for VEGFR2, FGFR1 and FGFR3, respectively. JK-P3 can inhibit VEGF-A-stimulated VEGFR2 activation and intracellular signalling, also inhibits endothelial monolayer wound closure and angiogenesis, as well as fibroblast growth factor receptor kinase activity in vitro. JK-P3 has anti-angiogenic activity .

HY-16961A

Sitravatinib malate MGCD516 malate; MG-516 malate	VEGFR c-Kit FLT3 Discoidin Domain Receptor Trk Receptor	Inflammation/Immunology Cancer
Sitravatinib malate (MGCD516 malate) is an orally bioavailable *receptor tyrosine kinase* (RTK) inhibitor with IC₅₀*s of 1.5 nM, 2 nM, 2 nM, 5 nM, 6 nM, 6 nM, 8 nM, 0.5 nM, 29 nM, 5 nM, and 9 nM for Axl, MER, VEGFR3, VEGFR2, VEGFR*1, KIT, FLT3, DDR2, DDR1, TRKA, TRKB, respectively . Sitravatinib malate shows potent single-agent antitumor efficacy and enhances the activity of PD-1 blockade through promoting an antitumor immune microenvironment .

HY-10260B

Vandetanib hydrochloride ZD6474 hydrochloride	VEGFR Autophagy Apoptosis	Cancer
Vandetanib hydrochloride (D6474 hydrochloride) is a potent, orally active inhibitor of *VEGFR2/KDR* tyrosine kinase activity (IC₅₀=40 nM). Vandetanib hydrochloride also has activity versus the tyrosine kinase activity of *VEGFR3/FLT4* (IC₅₀=110 nM) and *EGFR/HER1* (IC₅₀=500 nM) .

HY-120640

BMS-605541	VEGFR PDGFR	Cancer
BMS-605541 is a selective and orally active inhibitor of *VEGFR-2* kinase with an IC₅₀ value of 23 nM and K_i value of 49 nM. BMS-605541 inhibits the activity of Flk-1, *VEGFR-1* and PDGFR-β with IC₅₀ values of 40 nM, 400 nM and 200 nM, respectively. BMS-605541 can be used for cancer research .

HY-18711

SCR-1481B1 free base Metatinib free base; c-Met inhibitor 2 free base	c-Met/HGFR VEGFR	Cancer
SCR-1481B1 free base, also known as Metatinib free base, is a small molecule receptor kinase inhibitor that targets both c-MET and vascular endothelial growth factor receptor 2 (VEGFR2) .

HY-160686

GSK248233A	VEGFR	Others
GSK248233A is a dual inhibitor of Fluc and VEGFR2 with IC₅₀ of 1.03 μM and 2 nM, respectively. GSK248233A also shows activity against the AGC family. GSK248233A acts as a protein kinase inhibitor across ATP-dependent and -independent luciferases with potential implications for Fluc reporter assays .

HY-163471

PDGFRα/β/VEGFR-2-IN-1	PDGFR VEGFR	Cancer
PDGFRα/β/VEGFR-2-IN-1 (6f), a multiple PDGFRα/ and *VEGFR-2* tyrosine kinase inhibitor, particularly targets PDGFRα, PDGFRβ, and VEGFR-2 kinases with Nano molar concentrations .

HY-12047R

Ponatinib (Standard) AP24534 (Standard)	Reference Standards Bcr-Abl PDGFR VEGFR FGFR Src Autophagy	Cancer
Ponatinib (Standard) is the analytical standard of Ponatinib. This product is intended for research and analytical applications. Ponatinib (AP24534) is an orally active multi-targeted kinase inhibitor with IC₅₀s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for Abl, PDGFRα, *VEGFR2, FGFR1, and Src*, respectively .

HY-15333

ZK-261991	VEGFR	Inflammation/Immunology
ZK-261991 is an orally active *VEGFR* tyrosine kinase inhibitor with an IC₅₀ of 5 nM for VEGFR2.

HY-103002R

SU5408 (Standard) VEGFR2 kinase Inhibitor I (Standard)	Reference Standards VEGFR	Cardiovascular Disease
SU5408 (Standard) is the analytical standard of SU5408 (HY-103002). This product is intended for research and analytical applications. SU5408 (VEGFR2 Kinase Inhibitor I) is a potent and cell-permeable inhibitor of VEGFR2 kinase with an IC₅₀ of 70 nM.

HY-150027

Multi-kinase-IN-3	VEGFR PDGFR	Cancer
Multi-kinase-IN-3 (compound 2) is a potent angiokinase inhibitor. Multi-kinase-IN-3 shows inhibition activity against *VEGFR-2* and PDGFRβ, with IC₅₀ values of 58.3 and 55 nM, respectively .

Cat. No.	Product Name	Target	Research Area

HY-P5438

Srctide	Btk c-Kit FAK FLT3 Insulin Receptor	Others
Srctide is a biological active peptide. (This is a peptide substrate for many protein kinases, such as Blk, BTK, cKit, EPHA1, EPHB2, EPHB3, ERBB4, FAK, Flt3, IGF-1R, ITK, Lck, MET, MUSK, Ret, Src, TIE2, TrkB, VEGF-R1 (Flt-1) and VEGF-R2 (KDR).)

HY-P5527F

FAM-CSKtide	Peptides	Others
FAM-CSKtide is a biological active peptide. (This is a FAM labeled peptide substrate (Abs/Em = 494/521 nm) for C-terminal Src kinase (Csk) and many other kinases such as Axl, cKit, ERBB4, Fes, Flt3, IGF-1 R, MET, MUSK, PYK2, Ret, TIE2, TrkA, VEGF-R1 and VEGF-R2.)

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0135

Tanshinone IIA Maximum Cited Publications 36 Publications Verification Dan Shen ketone	Quinones Classification of Application Fields Terpenoids Labiatae Samanea saman (Jacq.) Merr. Diterpenoids Plants Naphthalene Quinones Disease Research Fields Source Classification Cancer	VEGFR
Tanshinone IIA (Tan IIA) is one of the main compositions in the root of Salvia miltiorrhiza Bunge. Tanshinone IIA may suppress angiogenesis by targeting the protein kinase domains of *VEGF/VEGFR2*.

HY-N0772

Isomangiferin 4 Publications Verification	Infection Structural Classification Liliaceae Xanthones Classification of Application Fields Phenols Polyphenols Anemarrhena asphodeloides Bunge Plants Disease Research Fields Source Classification	VEGFR NOD-like Receptor (NLR) NF-κB Bacterial AMPK Acetyl-CoA Carboxylase Apoptosis Reactive Oxygen Species (ROS) HSV Drug Derivative
Isomangiferin is an orally active xanthone C-glucoside, and its chemical structure is similar to Mangiferin (HY-N0290). Isomangiferin is an effective *VEGFR-2* kinase inhibitor, which can induces cell apoptosis, inhibit the growth, metastasis and angiogenesis of breast cancer. Isomangiferin exerts anti-inflammatory effects by inhibiting the HMGB1/NLRP3/NF-κB signaling pathway, thereby improving the renal function indicators of diabetic mice. Isomangiferin exhibits inhibitory effects on various bacteria and herpes simplex virus type 1 (HSV-1). Isomangiferin promotes the migration and osteogenic differentiation of bone marrow mesenchymal stem cells (BMSCs) and reduces cell apoptosis and the production of ROS by activating the AMPK/ACC pathway, thereby facilitating fracture healing .

HY-N8342

Rhamnazin 1 Publications Verification	Combretaceae Phenols Polyphenols Plants Combretum erythrophyllum Sond. Source Classification	VEGFR
Rhamnazin is an orally active inhibitor of VEGFR2 signaling with an IC₅₀ of 4.68 μM against *VEGFR2* kinase. Rhamnazin shows potent antiangiogenic activity and antitumor efficacy . Rhamnazin shows antioxidant and anti-inflammatory properties .

HY-N7177

Hydroxytanshinone IIA	Quinones Classification of Application Fields Labiatae Samanea saman (Jacq.) Merr. Plants Naphthalene Quinones Disease Research Fields Cancer Source Classification	Drug Metabolite VEGFR
Hydroxytanshinone IIA is a hydroxylated metabolite of Tanshinone IIA. Tanshinone IIA may suppress angiogenesis by targeting the protein kinase domains of *VEGF/VEGFR2* .

HY-N0135R

Tanshinone IIA (Standard) Dan Shen ketone (Standard)	Quinones Structural Classification Terpenoids Labiatae Samanea saman (Jacq.) Merr. Diterpenoids Plants Naphthalene Quinones Source Classification	Reference Standards VEGFR
Tanshinone IIA (Standard) is the analytical standard of Tanshinone IIA. This product is intended for research and analytical applications. Tanshinone IIA (Tan IIA) is one of the main compositions in the root of Salvia miltiorrhiza Bunge. Tanshinone IIA may suppress angiogenesis by targeting the protein kinase domains of VEGF/VEGFR2.

HY-N0772R

Isomangiferin (Standard)	Structural Classification Liliaceae Xanthones Phenols Polyphenols Anemarrhena asphodeloides Bunge Plants Source Classification	Reference Standards VEGFR NF-κB NOD-like Receptor (NLR) AMPK Acetyl-CoA Carboxylase Apoptosis Reactive Oxygen Species (ROS) HSV Drug Derivative
Isomangiferin (Standard) is the analytical standard of Isomangiferin (HY-N0772). This product is intended for research and analytical applications. Isomangiferin is an orally active xanthone C-glucoside, and its chemical structure is similar to Mangiferin (HY-N0290). Isomangiferin is an effective *VEGFR-2* kinase inhibitor, which can induces cell apoptosis, inhibit the growth, metastasis and angiogenesis of breast cancer. Isomangiferin exerts anti-inflammatory effects by inhibiting the HMGB1/NLRP3/NF-κB signaling pathway, thereby improving the renal function indicators of diabetic mice. Isomangiferin exhibits inhibitory effects on various bacteria and herpes simplex virus type 1 (HSV-1). Isomangiferin promotes the migration and osteogenic differentiation of bone marrow mesenchymal stem cells (BMSCs) and reduces cell apoptosis and the production of ROS by activating the AMPK/ACC pathway, thereby facilitating fracture healing.

Species:	Human (4) Cynomolgus (1)
Tag:	His (4) Avi (3) Fc (1)
Source:	HEK293 (4) Sf9 insect cells (1)

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P70552

	VEGFR-2 Protein, Human (HEK293, His) 1 Publications Verification Vascular endothelial growth factor receptor 2; KDR; VEGFR-2; Fetal liver kinase 1; FLK-1; kinase insert domain receptor; Protein-tyrosine kinase receptor flk-1; VEGFR2; VEGF R2	Human	HEK293
	VEGFR-2 is a tyrosine-protein kinase of the cell surface receptors of VEGFA, VEGFC, and VEGFD that mediates activation of the MAPK1/ERK2, MAPK3/ERK1, and MAP kinase signaling pathways, as well as the AKT1 signaling pathway. VEGFR-2 can promote the proliferation, survival, migration and differentiation of endothelial cells. Overexpression of VEGFR-2 is associated with the development of tumors. VEGFR-2 Protein, Human (HEK293, His) is the recombinant human-derived VEGFR-2 protein, expressed by HEK293 , with C-His labeled tag.

HY-P71421

	VEGFR-2 Protein, Human (HEK293, His-Avi) VEGFR2; VEGF R2; Vascular endothelial growth factor receptor 2; KDR; VEGFR-2; Fetal liver kinase 1; FLK-1; kinase insert domain receptor; Protein-tyrosine kinase receptor flk-1	Human	HEK293
	VEGFR-2 protein is a tyrosine protein kinase receptor for VEGFA, VEGFC and VEGFD and is critical in angiogenesis, blood vessel development and embryonic hematopoiesis. It promotes endothelial cell function and actin cytoskeletal reorganization. VEGFR-2 Protein, Human (HEK293, His-Avi) is the recombinant human-derived VEGFR-2 protein, expressed by HEK293 , with C-Avi, C-6*His labeled tag.

HY-P705690

	VEGFR-2 Protein, Human (Biotinylated, Sf9, His-Avi) KDR; kinase insert domain receptor (a type III receptor tyrosine kinase); FLK1; CD309; VEGFR; VEGFR2; Vascular endothelial growth factor receptor 2; VEGFR-2; kinase insert domain receptor; Protein-tyrosine kinase receptor Flk-1; EC 2.7.10.1; fetal liver kinase-1; soluble VEGFR2; tyrosine kinase growth factor receptor	Human	Sf9 insect cells
	VEGFR-2 protein is a tyrosine protein kinase receptor for VEGFA, VEGFC and VEGFD and is critical in angiogenesis, blood vessel development and embryonic hematopoiesis. It promotes endothelial cell function and actin cytoskeletal reorganization. VEGFR-2 Protein, Human (Biotinylated, Sf9, His) is the recombinant human-derived VEGFR-2, expressed by Sf9 insect cells, with GST labeled tag and biotin labeling..

HY-P70635

	VEGFR-2 Protein, Human (745a.a, HEK293, Fc) Vascular endothelial growth factor receptor 2; KDR; VEGFR-2; Fetal liver kinase 1; FLK-1; kinase insert domain receptor; Protein-tyrosine kinase receptor flk-1; VEGFR2; VEGF R2	Human	HEK293
	VEGFR-2 protein is a tyrosine protein kinase receptor for VEGFA, VEGFC and VEGFD and is critical in angiogenesis, blood vessel development and embryonic hematopoiesis. It promotes endothelial cell function and actin cytoskeletal reorganization. VEGFR-2 Protein, Human (745a.a, HEK293, Fc) is the recombinant human-derived VEGFR-2 protein, expressed by HEK293 , with C-hFc labeled tag.

HY-P703862

	VEGFR-2 Protein, Cynomolgus (Biotinylated, HEK293, His, Avi) kinase insert domain receptor	Cynomolgus	HEK293
	VEGFR-2 Protein, Cynomolgus (Biotinylated, HEK293, His, Avi) is the recombinant cynomolgus-derived VEGFR-2 protein, expressed by HEK293, with C-His & Avi tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-13016S

Cabozantinib-d6
Cabozantinib-d₆ is the deuterium labeled Cabozantinib. Cabozantinib is a potent multiple receptor tyrosine kinases (RTKs) inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC₅₀s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively .

HY-10065S

Axitinib-13C,d3
Axitinib- ¹³C,d₃ is a ¹³C-labeled and deuterium labeled Axitinib. Axitinib is a multi-targeted tyrosine kinase inhibitor with IC₅₀ values of 0.1, 0.2, 0.1-0.3, 1.6 nM for *VEGFR1, VEGFR2, VEGFR3* and PDGFRβ, respectively .

HY-10065S1

Axitinib-d3
Axitinib-d₃ (AG-013736-d₃) is deuterium labeled Axitinib. Axitinib is a multi-targeted tyrosine kinase inhibitor with IC₅₀s of 0.1, 0.2, 0.1-0.3, 1.6 nM for VEGFR1, VEGFR2, VEGFR3 and PDGFRβ, respectively .

HY-12047S

Ponatinib-d8
Ponatinib-d₈ (AP24534-d₈) is a deuterium labeled Ponatinib. Ponatinib (AP24534) is an orally active multi-targeted kinase inhibitor with IC50s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectively.

HY-13342AS

Apatinib-d8 free base

Apatinib-d₈ (free base) is the deuterium labeled Apatinib free base . Apatinib free base (YN968D1 free base) is an orally bioavailable tyrosine kinase inhibitor, which selectively targets VEGFR-2 (IC₅₀=1 nM). Apatinib free base (YN968D1 free base) is an anti-angiogenic drug for the research of advanced or metastatic gastric cancer. Apatinib free base (YN968D1 free base) potently inhibits Ret, c-Kit and c-Src with IC₅₀s of 13, 429 and 530 nM, respectively. It also inhibits cellular phosphorylation of VEGFR-2, c-kit and PDGFRβ .

HY-13016S1

Cabozantinib-d4
Cabozantinib-d₄ is deuterium labeled Cabozantinib. Cabozantinib is a potent multiple receptor tyrosine kinases (RTKs) inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC50s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.

HY-10255AS1

Sunitinib-d4
Sunitinib-d₄ is the deuterium labeled Sunitinib. Sunitinib (SU 11248) is a multi-targeted receptor tyrosine kinase inhibitor with IC₅₀s of 80 nM and 2 nM for VEGFR2 and PDGFRβ, respectively . Sunitinib, an ATP-competitive inhibitor, effectively inhibits autophosphorylation of Ire1α by inhibiting autophosphorylation and consequent RNase activation .

HY-10255AS

Sunitinib-d10
Sunitinib-d₁₀ (SU 11248-d₁₀) is a deuterium labeled Sunitinib. Sunitinib is a multi-targeted receptor tyrosine kinase inhibitor with IC₅₀s of 80 nM and 2 nM for VEGFR2 and PDGFRβ, respectively . Sunitinib, an ATP-competitive inhibitor, effectively inhibits autophosphorylation of Ire1α by inhibiting autophosphorylation and consequent RNase activation .

HY-15992S

BIBF 1202-13C,d3
BIBF 1202- ¹³C,d₃ is the ¹³C- and deuterium labeled BIBF 1202 (HY-15992). BIBF 1202 is the carboxylate metabolite of Nintedanib (HY-50904) which inhibits VEGFR2 kinase with an IC50 of 62 nM.

HY-50905S

Dovitinib-d8
Dovitinib-d₈ is the deuterium labeled Dovitinib. Dovitinib (CHIR-258) is a multi-targeted tyrosine kinase inhibitor with IC₅₀s of 1, 2, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, FGFR1/FGFR3, VEGFR1/VEGFR2/VEGFR3 and PDGFRα/PDGFRβ, respectively .

HY-W749733

BIBF 1202-d3
BIBF 1202-d₃ is the deuterium labeled BIBF 1202 (HY-15992). BIBF 1202 is the carboxylate metabolite of BIBF 1120 which inhibits VEGFR2 kinase with an IC₅₀ of 62 nM.

HY-10260S

Vandetanib-d6
Vandetanib-d₆ is the deuterium labeled Vandetanib. Vandetanib (D6474) is a potent, orally active inhibitor of VEGFR2/KDR tyrosine kinase activity (IC₅₀=40 nM). Vandetanib also has activity versus the tyrosine kinase activity of VEGFR3/FLT4 (IC₅₀=110 nM) and EGFR/HER1 (IC₅₀=500 nM) .

HY-10260S1

Vandetanib-d4
Vandetanib-d₄ is the deuterium labeled Vandetanib. Vandetanib (ZD6474) is a potent, orally active inhibitor of VEGFR2/KDR tyrosine kinase activity (IC₅₀=40 nM). Vandetanib also has activity versus the tyrosine kinase activity of VEGFR3/FLT4 (IC₅₀=110 nM) and EGFR/HER1 (IC₅₀=500 nM) .

HY-10260S2

Vandetanib-13C6
Vandetanib- ¹³C₆ is a ¹³C labeled Vandetanib (HY-10260) . Vandetanib (D6474) is a potent, orally active inhibitor of *VEGFR2/KDR* tyrosine kinase activity (IC₅₀=40 nM). Vandetanib also has activity versus the tyrosine kinase activity of *VEGFR3/FLT4* (IC₅₀=110 nM) and *EGFR/HER1* (IC₅₀=500 nM) .

HY-W706452

Cabozantinib-d4 S-malate
Cabozantinib-d₄ (S-malate) (XL184-d₄ (S-malate); BMS-907351-d₄ (S-malate)) is the deuterium labeled Cabozantinib (S-malate) (HY-12044). Cabozantinib S-malate (XL184 S-malate) is a potent multiple receptor tyrosine kinases inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC₅₀s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.

Host:	Mouse (1) Rabbit (2)
Reactivity:	Human (3) Rat (1) Mouse (2) Fish (1)
Application:	IHC-P (2) ICC/IF (3) IP (1) IHC-F (1) WB (3) ChIP (1) FC (1) ELISA (3)
Isotype:	IgG (2)
Conjugation:	Non-conjugated (3) Biotin (2)
Clonality:	Polyclonal (1) Monoclonal (2)
Modification:	Unmodified (3)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P81643

	VEGF Receptor 2 Antibody 2 Publications Verification KDR; FLK1; VEGFR2; Vascular endothelial growth factor receptor 2; VEGFR-2; Fetal liver kinase 1; FLK-1; kinase insert domain receptor; KDR; Protein-tyrosine kinase receptor flk-1; CD antigen CD309	WB, IHC-P, IHC-F, ICC/IF, ELISA	Human, Mouse
	VEGF Receptor 2 Antibody is a Rabbit-derived and non-conjugated IgG polyclonal antibody, targeting to VEGF Receptor 2.

HY-P85168

	VEGF Receptor 2 Antibody (YA4860) KDR; FLK1; VEGFR2; Vascular endothelial growth factor receptor 2; VEGFR-2; Fetal liver kinase 1; FLK-1; kinase insert domain receptor; KDR; Protein-tyrosine kinase receptor flk-1; CD antigen CD309	WB, ChIP, ICC/IF, FC, ELISA	Human, Fish
	VEGF Receptor 2 Antibody (YA4860) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to VEGF Receptor 2.

HY-P86118

	VEGF Receptor 2 Antibody (YA5810) Vascular endothelial growth factor receptor 2; VEGFR-2; Fetal liver kinase 1; FLK-1; kinase insert domain receptor; KDR; Protein-tyrosine kinase receptor flk-1; CD antigen CD309;	WB, IHC-P, ICC/IF, IP, ELISA	Human, Mouse, Rat
	VEGF Receptor 2 Antibody (YA5810) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to VEGF Receptor 2.